About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/21/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/21/2021.

Prospective Evaluation of Near-infrared Fluorescence Imaging Use as a Supportive Tool in Deep Infiltrating Endometriosis Surgery

Clinicaltrials.gov identifier NCT03935165

Recruitment Status Completed

First Posted May 2, 2019

Last update posted August 5, 2020

Study Description

Brief summary:

The aim of the study is to establish a new and more accurate method to visualize the peritoneal changes caused by endometriosis using Indocyanine Green mediated fluorescence imaging. The hypothesis is that Indocyanine Green, a fluorescent dye that has wide applications throughout medicine in identifying vascularity of tissues and neo-vascularization, could facilitate the localization and excision of endometriotic lesions exploiting the hypervascularization due to the chronic inflammation. The already published Pilot Study GRE-ENDO (Cosentino F, Near-Infrared Imaging with Indocyanine Green for Detection of Endometriosis Lesions (Gre-Endo Trial): A Pilot Study.), encouraged the effort of a larger prospective trial. Based on the mini-max two-stage design by Simon [Simon R. Optimal two stage design for phase II clinical trials], the investigators tested the null hypothesis that the true rate of pathologically assessed endometriosis would improve from 87% to the clinically relevant alternative of 100.0%, as assessed by NIR-ICG laparoscopy.

  • Condition or Disease:Pelvic Endometriosis
    Endometriosis Outside Pelvis
  • Intervention/Treatment: Drug: Indocyanine Green
  • Phase: Phase 2
Detailed Description

Patients were recruited within the clinical routine after indication for laparoscopy under consideration of the inclusion and exclusion criteria. The sample size was calculated according to the study design by Simon (Simon R. Optimal two stage design for phase II clinical trials), using an α-error of 0.01 (two-sided) and a β-error of 0.90. Considering a patient dropout of approximately 10%, the study was planned to enrol at least 47 women. The first abdominal and pelvi's inspection was made using direct laparoscope visualization under white light conditions. All areas suspected of peritoneal endometriosis was classified as white, black and red lesions and recorded together with their anatomic location in the surgical record for the purposes of subsequent extirpation. After the first visual inspection the patient was administered with 0.05 - 0.25 mg /(kg BW) Indocyanine Green intravenously. The Indocyanine Green imaging mode of the Olympus Indocyanine Green Imaging System was activated and suspected areas in Indocyanine Green imaging mode were recorded with them corresponding appearance in white light mode. If suspected areas were visible either in white light or Indocyanine Green imaging mode, specific sample has been taken from these areas. In addition, control biopsy specimens from inconspicuous peritoneum has been taken.

Study Design
  • Study Type: Interventional
  • Actual Enrollment: 51 participants
  • Intervention Model: Single Group Assignment
  • Intervention Model Description: In the selected patients, after a first white light visual inspection, 0.25 mg/(kg BW) ICG were injected intravenously. After 15 to 30 minutes a second inspection of the abdomen and pelvis in Near Infrared vision was made. All the visualized lesions were carefully described pre and post the Indocyanine Green injection, removed and listed
  • Masking: None (Open Label) ()
  • Primary Purpose: Diagnostic
  • Official Title: Indocyanine Green and Near-Infrared Vision in Deep Infiltrating Endometriosis Surgery. A Prospective Study (GRE-Endo-2 Trial)
  • Actual Study Start Date: January 2016
  • Actual Primary Completion Date: May 2019
  • Actual Study Completion Date: May 2019
Arms and interventions
Arm Intervention/treatment
Experimental: Indocyanine Green arm
All the patients to be enrolled have to meet the inclusion criteria. All enrolled patient is subjected, during laparoscopy, to an accurate inspection of the abdomen and all the visible endometriotic lesions are described. Subsequently, 0.25 mg /(kg BW) Indocyanine Green is administered intravenously during surgery and a second look of the abdomen and pelvis with the Near Infrared Vision is made, in order to identify the fluorescent lesions. All the lesions are described and localized pre and post the Indocyanine Green injection and then removed and properly cataloged.
Drug: Indocyanine Green
0.25 mg /(kg BW) Indocyanine Green PULSION®/ VERDYE Diagnostic Green® - Indocyanine Green is administered Intravenously
Outcome Measures
  • Primary Outcome Measures: 1. Localization of occult endometriotic lesion [ Time Frame: Intraoperative ]
    To detect occult endometriotic lesions, thanks to the fluorescence of the Indocyanine Green, that would remain otherwise not visible to the surgeon eye
  • Secondary Outcome Measures: 1. Sensibility and Specificity of Near Infrared Vision with Indocyanine green in detection of endometriotic lesions [ Time Frame: Intraoperative ]
    Optical qualitative assessment through the visual evaluation of a single expert surgeon (presence / absence of fluorescence, due to the injection of the Indocyanine Green and the use of the Near Infrared vision, at the level the of suspected endometriotic lesions)
  • 2. Operatory Time [ Time Frame: Intraoperative ]
    To assess if the use of Indocyanine Green cause a significant increase of the operatory time
  • 3. Complications [ Time Frame: From operatory room up to 3 days ]
    To assess if the use of Indocyanine Green increase the percentage of intra and post-operative complications
  • 4. Side effects [ Time Frame: From operatory room up to 3 days ]
    Evaluation of possible side effects related to the use of Indocyanine Green as a fluorescent endometriosis' marker
Eligibility Criteria
  • Ages Eligible for Study: 18 to 50 Years (Adult)
  • Sexes Eligible for Study: Female
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Suspected endometriosis with necessity for laparoscopic confirmation and resection

- Regular menstrual cycles

Exclusion Criteria:

- Patients younger than 18 years and older than 50 years at time of operation

- Subject with previous history of adverse reaction or allergy to Indocyanine Green,
iodine, shellfish or iodine dyes

- Documented allergy to sulfur containing compounds

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to Indocyanine Green

- Subject has significant liver disease, cirrhosis or liver insufficiency with abnormal
liver function tests (Total bilirubin increased by factor 1.5 than normal and/or serum
glutamic oxaloacetic transaminase increased by factor 2 than normal)

- Subject has uremia, serum creatinine (> 2.0 mg/dl)

- Subject has severe coronary heart disease (instable angina pectoris)

- Pregnant or breast-feeding women

- Subject actively participating in another drug, biologic and/or device protocol

- The presence of medical conditions contraindicating general anesthesia or standard
surgical approaches

- Subject has any medical condition, which in the judgment of the Investigator and/or
designee makes the subject a poor candidate for the investigational procedure

Contacts and Locations
Contacts
Locations

Italy, RM
Catholic University of Sacred Heart
Rome

Sponsors and Collaborators

Catholic University of the Sacred Heart

Investigators

Principal Investigator: Francesco Cosentino, MD Fondazione di Ricerca e Cura Giovanni Paolo II , Campobasso , Italy

More Information